Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (Anti-EpCAM x anti-CD3)

Cancer Research

Volumn 72, Issue 1, 2012, Pages 24-32

  Jäger, Michael ^a   Schoberth, Alexandra ^a   Ruf, Peter ^a   Hess, Juergen ^b   Hennig, Michael ^b   Schmalfeldt, Barbara ^b   Wimberger, Pauline ^c   Stroḧlein, Michael ^d,e   Theissen, Bettina ^b   Heiss, Markus M ^d   Lindhofer, Horst ^a,b  

^a TRION Research GmbH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CATUMAXOMAB; CD133 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; VASCULOTROPIN;

ARTICLE; ASCITES CELL; ASCITES TUMOR; CANCER STEM CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOLOGICAL MONITORING; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PARACENTESIS; PERITONEAL FLUID; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ANTIBODIES, BISPECIFIC; ASCITES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; LYMPHOCYTE ACTIVATION; MONITORING, PHYSIOLOGIC;

EID: 84855401998     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2235     Document Type: Article

References (39)

1. Parsons SL, Watson SA, Steele RJ. Malignant ascites. Br J Surg 1996;83:6-14. (Pubitemid 26018797)
2. Hird V, Thomas H, Stewart JS, Epenetos AA. Malignant ascites: review of the literature, and an update on monoclonal antibodytargeted therapy. Eur J Obstet Gynecol Reprod Biol 1989;32: 37-45. (Pubitemid 19182724)
3. Feldman GB, Knapp RC. Lymphatic drainage of the peritoneal cavity and its significance in ovarian cancer. Am J Obstet Gynecol 1974;119:991-4.
4. Garrison RN, Galloway RH, Heuser LS. Mechanisms of malignant ascites production. J Surg Res 1987;42:126-32. (Pubitemid 17024827)
5. Bronskill MJ, Bush RS, Ege GN. A quantitative measurement of peritoneal drainage in malignant ascites. Cancer 1977;40:2375-80. (Pubitemid 8245231)
6. Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000;83:261-6. (Pubitemid 30411727)
7. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999;163:1246-52. (Pubitemid 29352740)
8. Riesenberg R, Buchner A, Pohla H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J Histochem Cytochem 2001;49:911-7. (Pubitemid 32565984)
9. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004;35:122-8. (Pubitemid 38133932)
10. Heiss MM, Strohlein MA, Jager M, Kimmig R, Burges A, Schoberth A, et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005;117:435-43. (Pubitemid 41429567)
11. Burges A, Wimberger P, Kumper C, Gorbounova V, Sommer H, Schmalfeldt B, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti- CD3 antibody: a phase I/II study. Clin Cancer Res 2007;13:3899-905. (Pubitemid 47037597)
12. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010;127: 2209-21.
13. Stroehlein MA. Catumaxomab treatment significantly improves overall survival in patients with malignant ascites: follow-up results from a pivotal phase II/III study [abstract]. In: Proceedings of the 22nd International Congress on Anti Cancer Treatment; 2011 Feb 1-4; Paris, France.
14. Curiel TJ,Coukos G, Zou L, Alvarez X,Cheng P,Mottram P, et al.Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9. (Pubitemid 39273735)
15. Ruf P, Gires O, Jager M, Fellinger K, Atz J, Lindhofer H. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer 2007;97: 315-21. (Pubitemid 47196752)
16. Mulligan JK, Rosenzweig SA, Young MR. Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2. J Immunother 2010;33:126-35.
17. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999;6:373-8. (Pubitemid 29260800)
18. Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 2009;14:1242-51.
19. Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 2010;36:458-67.
20. Cambiaggi C, Scupoli MT, Cestari T, Gerosa F, Carra G, Tridente G, et al. Constitutive expression of CD69 in interspecies T-cell hybrids and locus assignment to human chromosome 12. Immunogenetics 1992;36:117-20.
21. Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol 2007;18:460-6. (Pubitemid 350116595)
22. Alison MR, Murphy G, Leedham S. Stem cells and cancer: a deadly mix. Cell Tissue Res 2008;331:109-24. (Pubitemid 350265500)
23. Anderson EC, Hessman C, Levin TG, Monroe MM, Wong MH. The role of colorectal cancer stem cells in metastatic disease and therapeutic response. Cancers 2011;3:319-39.
24. Cho RW, Clarke MF. Recent advances in cancer stem cells. Curr Opin Genet Dev 2008;18:48-53. (Pubitemid 351694448)
25. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007;58:267-84. (Pubitemid 46706514)
26. + cancer stem cells in childhood malignant melanoma and its correlation with metastasis. Mod Pathol 2010;23:376-80.
27. Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S, et al. CD133 antigen expression in ovarian cancer. BMC Cancer 2009;9:221-30.
28. Ferrandina G, Petrillo M, Bonanno G, Scambia G. Targeting CD133 antigen in cancer. Expert Opin Ther Targets 2009;13:823-37.
29. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 2009;27:844-50.
30. Mizrak D, Brittan M, Alison MR. CD133: molecule of the moment. J Pathol 2008;214:3-9.
31. WuY,WuPY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev 2009;18:1127-34.
32. Al-Hajj M. Cancer stem cells and oncology therapeutics. Curr Opin Oncol 2007;19:61-4. (Pubitemid 44885602)
33. Besancon R, Valsesia-Wittmann S, Puisieux A, de Fromentel CC, Maguer-Satta V. Cancer stem cells: the emerging challenge of drug targeting. Curr Med Chem 2009;16:394-416.
34. Ward RJ, Dirks PB. Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol 2007;2:175-89. (Pubitemid 46448063)
35. Zhou J, Zhang Y. Cancer stem cells: models, mechanisms and implications for improved treatment. Cell Cycle 2008;7:1360-70. (Pubitemid 351872574)
36. - metastatic colon cancer cells initiate tumors. J Clin Invest 2008;118:2111-20.
37. Hassan MI, Kassim SK, Saeda L, Laban M, Khalifa A. Ovarian cancerinduced immunosuppression: relationship to tumor necrosis factoralpha (TNF-alpha) release from ovarian tissue. Anticancer Res 1999; 19:5657-62. (Pubitemid 30093346)
38. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of antitumour activity. Nat Rev Cancer 2008;8:579-91.
39. Stoelcker B, Echtenacher B, Weich HA, Sztajer H, Hicklin DJ, Mannel DN. VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence. J Interferon Cytokine Res 2000;20:511-7. (Pubitemid 30414234)